Int J Rheum Dis:大剂量静脉激素冲击治疗对白塞眼病

2017-07-14 姚中强 中国风湿病公众论坛

大剂量静脉激素冲击治疗对白塞眼病的视力改善更好且复发更少

目的:评估静脉大剂量甲级强的松龙冲击治疗白塞眼病的疗效。

方法:这是一个双盲对照试验,我们随机把有后色素膜炎和/视网膜血管炎的白塞病患者分为两组。他们或者接受静脉甲级强的松龙冲击治疗(1000 mg?甲强龙)或者空白药物连续3天。两组均接受静脉环磷酰胺、硫唑嘌呤和泼尼松龙联合治疗6个月。计算每一个患者的视敏度、基于每只眼睛每一段的炎症状态的病情活动性评分(DAI)?、总炎症活动性评分?(TIAI)?和调整后的病情活动性评分。用配对t检验和Mann-Whitney U检验来进行统计分析。

结果:每组各17名患者完成了试验。试验组平均视敏度从0.5增加到0.8(P < 0.000001),空白对照组视敏度从0.6增加到0.7(P < 0.02)?,两组间有显着统计学差异(P = 0.01)。两组病情活动性评分的改善无显着差异(P > 0.2):?后色素膜炎:1.9降低到0.5 (P < 0.0006) vs 2.3?降到0.8(P < 0.0002);?视网膜血管炎:4.0?降到1.1 (P < 0.0004) vs 3.1降到1.1(P < 0.0005);?总炎症活动性评分:23?降到5.7(P < 0.0002) vs 24.8降到8.4 (P < 0.003);?调整后的总病情活动性评分:24.1降到7.3 (P < 0.0002) vs 25.9?降到7.9 (P < 0.004)。试验组1例复发,对照组7例?(P < 0.005)。

结论:对严重白塞眼病来说,在常规联合治疗基础上增加大剂量激素冲击治疗,可能治疗6月之内视力改善更好,复发更少。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697503, encodeId=2d2f169e50326, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jan 20 14:40:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800091, encodeId=c769180009114, content=<a href='/topic/show?id=8dcfe167206' target=_blank style='color:#2F92EE;'>#白塞眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71672, encryptionId=8dcfe167206, topicName=白塞眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Sat Nov 18 18:40:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012315, encodeId=26fa201231534, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 28 21:40:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540498, encodeId=539015404989e, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578672, encodeId=b7fa15e8672fd, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222206, encodeId=d25e222206f0, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Jul 14 11:24:40 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222168, encodeId=8e492221689d, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jul 14 10:34:52 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2018-01-20 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1697503, encodeId=2d2f169e50326, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jan 20 14:40:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800091, encodeId=c769180009114, content=<a href='/topic/show?id=8dcfe167206' target=_blank style='color:#2F92EE;'>#白塞眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71672, encryptionId=8dcfe167206, topicName=白塞眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Sat Nov 18 18:40:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012315, encodeId=26fa201231534, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 28 21:40:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540498, encodeId=539015404989e, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578672, encodeId=b7fa15e8672fd, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222206, encodeId=d25e222206f0, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Jul 14 11:24:40 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222168, encodeId=8e492221689d, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jul 14 10:34:52 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1697503, encodeId=2d2f169e50326, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jan 20 14:40:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800091, encodeId=c769180009114, content=<a href='/topic/show?id=8dcfe167206' target=_blank style='color:#2F92EE;'>#白塞眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71672, encryptionId=8dcfe167206, topicName=白塞眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Sat Nov 18 18:40:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012315, encodeId=26fa201231534, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 28 21:40:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540498, encodeId=539015404989e, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578672, encodeId=b7fa15e8672fd, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222206, encodeId=d25e222206f0, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Jul 14 11:24:40 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222168, encodeId=8e492221689d, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jul 14 10:34:52 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1697503, encodeId=2d2f169e50326, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jan 20 14:40:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800091, encodeId=c769180009114, content=<a href='/topic/show?id=8dcfe167206' target=_blank style='color:#2F92EE;'>#白塞眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71672, encryptionId=8dcfe167206, topicName=白塞眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Sat Nov 18 18:40:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012315, encodeId=26fa201231534, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 28 21:40:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540498, encodeId=539015404989e, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578672, encodeId=b7fa15e8672fd, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222206, encodeId=d25e222206f0, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Jul 14 11:24:40 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222168, encodeId=8e492221689d, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jul 14 10:34:52 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-16 pps20023
  5. [GetPortalCommentsPageByObjectIdResponse(id=1697503, encodeId=2d2f169e50326, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jan 20 14:40:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800091, encodeId=c769180009114, content=<a href='/topic/show?id=8dcfe167206' target=_blank style='color:#2F92EE;'>#白塞眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71672, encryptionId=8dcfe167206, topicName=白塞眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Sat Nov 18 18:40:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012315, encodeId=26fa201231534, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 28 21:40:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540498, encodeId=539015404989e, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578672, encodeId=b7fa15e8672fd, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222206, encodeId=d25e222206f0, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Jul 14 11:24:40 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222168, encodeId=8e492221689d, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jul 14 10:34:52 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1697503, encodeId=2d2f169e50326, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jan 20 14:40:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800091, encodeId=c769180009114, content=<a href='/topic/show?id=8dcfe167206' target=_blank style='color:#2F92EE;'>#白塞眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71672, encryptionId=8dcfe167206, topicName=白塞眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Sat Nov 18 18:40:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012315, encodeId=26fa201231534, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 28 21:40:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540498, encodeId=539015404989e, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578672, encodeId=b7fa15e8672fd, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222206, encodeId=d25e222206f0, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Jul 14 11:24:40 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222168, encodeId=8e492221689d, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jul 14 10:34:52 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-14 139****5926

    好好文章学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1697503, encodeId=2d2f169e50326, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jan 20 14:40:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800091, encodeId=c769180009114, content=<a href='/topic/show?id=8dcfe167206' target=_blank style='color:#2F92EE;'>#白塞眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71672, encryptionId=8dcfe167206, topicName=白塞眼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Sat Nov 18 18:40:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012315, encodeId=26fa201231534, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 28 21:40:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540498, encodeId=539015404989e, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578672, encodeId=b7fa15e8672fd, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Jul 16 00:40:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222206, encodeId=d25e222206f0, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Jul 14 11:24:40 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222168, encodeId=8e492221689d, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jul 14 10:34:52 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-14 楠博One

    学习谢谢分享

    0

相关资讯

住院医师牢记—常用静脉泵入药物汇总

住院医师牢记—常用静脉泵入药物汇总

Circulation:非O型血的人静脉和动脉血栓事件的发生率较高

ABO血型已显示出能够增加静脉血栓栓塞和动脉疾病的风险。然而,该联系的报告的幅度并不一致,并且只是基于小型研究的证据。研究人员使用献血者的SCANDAT2数据库与其他全国性的健康数据寄存器链接调查了ABO血型和复发性静脉血栓和动脉事件的发生率之间的关联。在1987年和2012年间丹麦和瑞典的献血者中,研究人员随访了血栓和动脉事件的诊断。泊松回归模型被用于估计发病率比(IRR)作为相对风险的措施。在

JAMA证据点评:住院儿童应用等张与低张静脉补液的比较

临床问题在儿童维持静脉输液疗法中,与低张液相比,等张液是否与低钠血症的发生率较低相关? 要点与低张液相比,等张液与低钠血症的发生率较低相关,且没有不良转归增多的证据。 与血浆相比,低张液所含的钠较少,常规处方用于维持儿童的水合状态。输注低张液可引起低钠血症,并且与包括脑水肿和死亡在内的不良转归相关1。 这篇JAMA临床证据概要总结了一项近期的Cochrane综述,该综述比较了采用等张

大盘点| 常见静脉用抗高血压药物

一、常见静脉用抗高血压药物二、详细讲解►硝普钠1)作用机制:动脉和静脉扩张剂。2)给药剂量:静脉滴注,从0.5 µg/kg/min开始,维持剂量3 µg/kg/min,极量10 µg/kg/min,总量3.5 mg/kg。3)起效时间:即刻。4)持续时间:1-10min。5)不良反应:轻微。主要有:a、眩晕,肌颤,出汗,心动过速等;b、硫氰酸盐超量或中毒;c、氰化物中毒;d、光敏感、高铁血红蛋

专题:了解静脉血栓前沿指南,改善患者远期预后

静脉血栓栓塞症是临床上常见的疾病之一,它常并发于其他疾病,是医院内非预期死亡的重要原因。该疾病已经成为临床医生面临的严峻问题。静脉血栓栓塞症发病隐匿,临床症状不典型,容易被临床医生忽视,为了对该疾病做到早发现、早诊断及规范治疗,梅斯小编整理静脉血栓的相关指南,供大家参考。 一、深静脉血栓的预防及管理 1、2016 ESO指南:无活动能力急性缺血性卒中患者静脉血栓栓塞的预防 

人体静脉注入多少气体才致死 ?

大量气体短时间内进入血循环或原溶于血液内的气体迅速游离,形成气泡阻塞心血管,我们称为气体栓塞。气体栓塞多由于静脉损伤破裂,外界气体由静脉缺损处进入血流所致。如头颈手术、胸壁和肺创伤损伤静脉、使用正压静脉输液以及人工气胸或气腹误伤静脉时,气体可被吸气时因静脉腔内的负压吸引,由损伤口进入静脉。